At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Nab-paclitaxel +3 moredrug
Likely dose
Nab-paclitaxel 260mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-2 Trial)
In Brief
A Phase 2 clinical trial evaluating Nab-paclitaxel, Cisplatin, and 2 other interventions for Head and Neck Squamous Cell Carcinoma. Completed, enrolled 40 participants across 1 site.
Detailed Summary
To explore the efficiency and safety of TP chemotherapy, tislelizumab, combined with afatinib as a new neoadjuvant treatment regimen for patients with resectable HNSCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartSep 2022
Primary CompletionOct 2023
Study CompletionDec 2024
TodayJul 2026
First PostedAug 25, 2022
Enrollment StartSep 12, 2022
Primary CompletionOct 29, 2023
Study CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 3.9 years ago
Interventions
Nab-paclitaxeldrug
260mg/m\^2 IV Q3W
Cisplatindrug
75mg/m\^2 IV Q3W
Tislelizumabbiological
200mg IV Q3W
Afatinibdrug
30mg PO QD